All

Phase 2 ProHear Study Reaches 50% Patient Enrollment

Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.

Oncologist Researching Cisplatin Alternative for Cancer Patients
Sensorion Enrolls Last Patient in Clinical Trial of Drug to Prevent Cisplatin-Induced Ototoxicity
How Chronic Illnesses Impact Hearing, Balance, and Cognition: A Guide for Hearing Care Professionals
Sensorion to Lead Symposium on Hearing Loss Treatment
Acousia to Present PROHEAR Study on Hearing Loss Treatment for Cancer Patients
Sensorion Gets Positive Recommendation for Clinical Trial of Drug Candidate for Cisplatin-Induced Ototoxicity

All

Study Details Chemo Drug Effect on Hearing Loss in Cancer Survivors

A study found that 78% of testicular cancer survivors treated with cisplatin-based chemotherapy experience significant hearing difficulties.

Sensorion Announces Disappointing Results from SSNHL Drug Trial

Tag: cisplatin ototoxicity

All

Phase 2 ProHear Study Reaches 50% Patient Enrollment

Oncologist Researching Cisplatin Alternative for Cancer Patients

Sensorion Enrolls Last Patient in Clinical Trial of Drug to Prevent Cisplatin-Induced Ototoxicity

How Chronic Illnesses Impact Hearing, Balance, and Cognition: A Guide for Hearing Care Professionals

Sensorion to Lead Symposium on Hearing Loss Treatment

Acousia to Present PROHEAR Study on Hearing Loss Treatment for Cancer Patients

Sensorion Gets Positive Recommendation for Clinical Trial of Drug Candidate for Cisplatin-Induced Ototoxicity

All

Study Details Chemo Drug Effect on Hearing Loss in Cancer Survivors

Sensorion Announces Disappointing Results from SSNHL Drug Trial

All

Sorry, No Posts Found

Sorry, No Posts Found

The Hearing Review

Our Parent Company

Key Resources

Helpful Links